UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000004843
Receipt number R000005698
Scientific Title Evaluate of Tolterodine for lower urinary tract syndrome after prostate Brachytherapy
Date of disclosure of the study information 2011/01/20
Last modified on 2011/01/08 10:13:16

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluate of Tolterodine for lower urinary tract syndrome after prostate Brachytherapy

Acronym

Evaluate and safety of Tolterodine for lower urinary tract syndrome after prostate Brachytherapy

Scientific Title

Evaluate of Tolterodine for lower urinary tract syndrome after prostate Brachytherapy

Scientific Title:Acronym

Evaluate and safety of Tolterodine for lower urinary tract syndrome after prostate Brachytherapy

Region

Japan


Condition

Condition

Prostate cancer

Classification by specialty

Urology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate efficacy and the safety of combination therapy with Tolerodine for the patient who remained storage symptom treated by alfa-1 blocker after treatment of prostate Brachytherapy

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

To verify change rate of Overactive Bladder symptom score(OABSS) after 8week

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Single blind -participants are blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Urief tab(4mg b.i.d) 12week

Interventions/Control_2

Detrusitol cap(4mg, daily) 8week

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

40 years-old <=

Age-upper limit

80 years-old >

Gender

Male

Key inclusion criteria

-40<or=age80
-Patient to whom alfa-1-blocker is administered after treatment for prostate brachytherapy
-OABSS(Q3)>or=2, OABSS(total)>or=3

Key exclusion criteria

1. PVR>or=100cc
2. Patient with urinary tract infection
3. Patient of anti-cholinergic medicine administration taboo
a. Patient with urinary retention
b. Patient whose pylorus or duodenum or ileum are obstructed, or who has paralytic ileus
c. Patient whose digestive organ movement or tention are decreased
d. Patient with narrow-angle glaucoma
e. Patient with myasthenia gravis
f. Patient with severe heart disease
g. Patient with sevre hepatic dysfunction (Child-Pugh classification C)
h. Patient with hypersentivity for anti-cholinergic medicine

Target sample size

32


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hirohiko Nagata

Organization

Keio University School of Medicine

Division name

Department of Urology

Zip code


Address

35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name Hirohiko Nagata

Organization

Keio University School of Medicine

Division name

Department of Urology

Zip code


Address


TEL

03-3353-1211

Homepage URL


Email



Sponsor or person

Institute

Keio University Shool of Medicine
Department of Urology

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2011 Year 01 Month 20 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2011 Year 01 Month 06 Day

Date of IRB


Anticipated trial start date

2011 Year 02 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2011 Year 01 Month 08 Day

Last modified on

2011 Year 01 Month 08 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005698


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name